Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Braveheart Bio, Inc. (BRVE : NSDQ)

• Company Description    Braveheart Bio Inc. is a clinical-stage biopharmaceutical company. It focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor for the treatment of obstructive HCM and non-obstructive HCM. Braveheart Bio Inc. is headquartered in San Francisco, California. Number of Employees: 30

• Price / Volume Information    Yesterday's Closing Price: $26.74 Daily Weekly Monthly 20 Day Moving Average: 326,312 shares Shares Outstanding: 73.15 (millions) Market Capitalization: $1,956.11 (millions) Beta: 52 Week High: $32.00 52 Week Low: $24.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.87% -2.44% 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE LETTERMAN DR.BLDG. A STE. A4-300 - SAN FRANCISCO,CA 94129 USA ph: 415-707-6312 fax: - ir@braveheart.bio http://www.braveheart.bio

• General Corporate Information    Officers Travis Murdoch - Chief Executive Officer and President Christopher Viehbacher - Chairman J. Paul Rickey - Chief Financial Officer Vineeta Agarwala - Director Jasper Bos - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 10567X101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 73.15 Most Recent Split Date: (:1) Beta: Market Capitalization: $1,956.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.39 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.98 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - - 12/31/25 - - Current Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - - Quick Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - - Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - - 12/31/25 - - Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©